Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability

被引：0

作者：

Wehrmann, C. ^{[1
]}

Senftleben, S. ^{[1
]}

Baum, R. P. ^{[1
]}

机构：

[1] Zentralklin Bad Berka GmbH, Bad Berka, Germany

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：S178 / S179

页数：2

共 50 条

[1] Lu-177 DOTA-TATE for peptide receptor Radionuclide therapy (PRRT): Organ, tumor, and blood kinetics
Wehrmann, C.
Senftleben, S.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S359
[2] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
Wehrmann, C.
Senftleben, S.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
[3] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
Wehrmann, C.
Senftleben, S.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
[4] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
Wehrmann, C.
Senftleben, S.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
[5] Dosimetry in peptide receptor radionuclide therapy (PRRNT): comparative results using Lu-177 DOTA-TATE, DOTA-NOC und DOTA-TOC
Schuchardt, C.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S244 - S244
[6] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
Wehrmann, Christiane
Senftleben, Stefan
Zachert, Carolin
Mueller, Dirk
Baum, Richard P.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
[7] Survival benefits and efficacy of peptide receptor radionuclide therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in pancreatic neuroendocrine tumor (pNET)
Prasad, V.
Hoersch, D.
Hommann, M.
Zachert, C.
Baum, R. P.
JOURNAL OF NUCLEAR MEDICINE, 2009, 50
[8] Pancreatic Neuroendocrine Tumor (pNET): Survival Benefits and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Using Y-90/Lu-177 DOTA-TATE
Prasad, V
Hoersch, D.
Hommann, M.
Zachert, C.
Baum, R. P.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 133
[9] Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long term follow-up
Prasad, V.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
[10] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
Mc Ewan, A.
Wieler, M.
Makis, W.
McMullen, T.
Morrish, D.
MacLeod, S.
Schrader, L.
Sawyer, M.
NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94

← 1 2 3 4 5 →